AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells therapy(Stanford University)

N/A

Report date: 2024/05/21 20:00:08

Base Information

Drug NameAutologousCD22 Chimeric Antigen Receptor (CAR)T Cells therapy(Stanford University)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsCD22 modulators
TargetsCD22
Therapy Area/IndicationsWaldenstrom MacroglobulinemiaLymphoma, Mantle-CellLymphoma, Follicular +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesStanford UniversityThe Leukemia And Lymphoma Society
China Registration ClassN/A

Develop Information

Active CompaniesStanford UniversityThe Leukemia And Lymphoma Society
Inactive CompaniesN/A
Active IndicationsWaldenstrom MacroglobulinemiaLymphoma, Mantle-CellLymphoma, Follicular +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A